Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 16/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233808 | 0.90 | UTS2R (0.41) | UTS2RKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL636473 | 0.89 | UTS2R (0.40) | UTS2RKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL636831 | 0.88 | UTS2R (0.39) | UTS2RHRH4HRH3LMNAHTT | |
| SCHEMBL349376 | 0.88 | FOLH1 (0.42) | HTT | |
| SCHEMBL4755055 | 0.86 | UTS2R (0.42) | UTS2RHRH4HRH3LMNAHTT | |
| SCHEMBL6684836 | 0.85 | SMN1; SMN2 (0.48) | UTS2RKMT2AHRH4HRH3SMN1; SMN2 | |
| SCHEMBL2230567 | 0.84 | UTS2R (0.40) | UTS2RKMT2A | |
| SCHEMBL638092 | 0.84 | HRH4 (0.39) | UTS2RHRH4HRH3LMNAHTT | |
| SCHEMBL4754537 | 0.83 | UTS2R (0.47) | UTS2R | |
| SCHEMBL2230681 | 0.83 | UTS2R (0.42) | UTS2RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | ARBOR PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | ARBOR PHARMACEUTICALS, LLC | 2018-09-13 | — | — | US | disclosed |
| US-9944592-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-1660440-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009646-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-2354120-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XenoPort, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | XENOPORT, INC. | 2009-09-17 | — | — | US | disclosed |
| US-7572830-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| WO-2008157408-A2 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | XENOPORT, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7300956-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070054945-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-7109239-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1660440-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | Xenoport, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005019163-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | UTS2R 1572/4885KMT2A 2442/4885HRH4 123/4885 |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | UTS2R 1572/4885KMT2A 2442/4885HRH4 123/4885 |
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | UTS2R 1572/4885KMT2A 2442/4885HRH4 123/4885 |
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | UTS2R 1572/4885KMT2A 2442/4885HRH4 123/4885 |
| US-20070054945-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | UTS2R 1572/4885KMT2A 2442/4885HRH4 123/4885 |
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | APEH, ABAT, GABARAPL1 | UTS2R 1377/4885KMT2A 2415/4885HRH4 130/4885 |
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | UTS2R 1572/4885KMT2A 2442/4885HRH4 123/4885 |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | UTS2R 1572/4885KMT2A 2442/4885HRH4 123/4885 |
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | GABBR2, GABBR1, GABRB1 | UTS2R 989/4885KMT2A 1808/4885HRH4 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.